Identification of poor prognostic joint locations in an early rheumatoid arthritis cohort at risk of rapidly progressing disease: a post-hoc analysis of the Phase III AGREE study

by Patrick Durez, Rene Westhovens, Femke Baeke, Yedid Elbez, Sofie Robert, Harris A. Ahmad
Published 2022-04-01

Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting

by Rieke Alten, Harald Burkhardt, Eugen Feist, Klaus Krüger, Juergen Rech, Andrea Rubbert-Roth, Reinhard E. Voll, Yedid Elbez, Christiane Rauch
Published 2018-01-01

Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept

by Harris A. Ahmad, Joshua F. Baker, Philip G. Conaghan, Paul Emery, Thomas W. J. Huizinga, Yedid Elbez, Subhashis Banerjee, Mikkel Østergaard
Published 2022-02-01

Real-world predictors of 12–month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study

by Xavier Mariette, Alain Cantagrel, Rieke Alten, Manuela Le Bars, Yedid Elbez, Hanns-Martin Lorenz, Mauro Galeazzi, Hubert G Nüßlein, Melanie Chartier, Christiane Rauch
Published 2017-12-01

The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phas...

by Paul Emery, Yoshiya Tanaka, Vivian P. Bykerk, Clifton O. Bingham, Thomas W. J. Huizinga, Gustavo Citera, Kuan-Hsiang Gary Huang, Chun Wu, Sean E. Connolly, Yedid Elbez, Robert Wong, Karissa Lozenski, Roy Fleischmann
Published 2023-04-01